RPS9 and Alzheimer disease: While we can formally not rule out that the Rps9 D95N mutation may accelerate the development of AD-associated phenotypes in the humanized APP mice, we consider this possibility unlikely, as our analysis of 15 months old mice testifies to the complete absence of a Rps9 D95N mutation effect on AD-associated pathology.